![]() The final ratio numbers will be determined on the record date based on the HCMC shares outstanding on such date.ĭo I need to do anything to get my dividend shares? At present, we anticipate the ratio being approximately 71,000 to 1, meaning, for every 71,000 shares of HCMC common stock owned, a shareholder will receive one (1) share of HCWC common stock. The calculation for the dividend will be based upon the number of qualifying shares of HCMC divided by the amount of initially issued shares of HCWC. Fractional shares will not be issued, and fractional shares will not be rounded up. The amount of HCWC shares issued to each shareholder of HCMC will be based directly on the percentage of ownership of HCMC stock on the record date, subject to certain minimum ownership amounts. How many dividend shares of HCWC common stock will I be receiving? Therefore, you should own your stock no later than April 26, 2023, and hold the stock through May 1, 2023. To ensure you are deemed an owner of HCMC common stock on that date, you should own or purchase the HCMC common stock at least three business days BEFORE May 1, 2023. The record date to own shares to participate in the dividend is May 1, 2023. When do I need to own HCMC common stock in order to receive dividend shares in HCWC? In particular, the FAQs relate to the upcoming record date and steps necessary to be eligible for HCMC’s dividend of common stock of HCWC. (HCWC), HCMC’s natural foods grocery and wellness business. (OTC Pink: HCMC) released the following frequently asked questions (FAQs) and related answers in connection with its expected Spin-Off of Healthy Choice Wellness Corp. In this collaborative study, Kao and Maruho took samples of sebum from patients with severe AD to identify characteristics of their SSL-RNA and factors that change depending on the severity of disease.HOLLYWOOD, FL, Ap(GLOBE NEWSWIRE) - Today Healthier Choices Management Corp. In actual clinical settings, however, techniques for determining the severity of patients with severe AD as well as those with mild/moderate AD are needed. Kao has already reported that RNA expression profile in sebum reflects characteristics of adult and infant patients with AD *3, although those studies were conducted in patients with mild-to-moderate AD. The SSL-RNA monitoring technology, which was reported by Kao in 2019 *3, allows the easy collection of RNA from facial sebum for analysis without damaging the skin. Therefore, a new technology to determine the severity of AD noninvasively, easily and accurately has been long awaited. Furthermore, it has been found that TARC may show unexpected values during the administration of therapeutic drugs for AD and thus may not correctly reflect the severity of AD. However, the location of blood sampling is restricted and might induce pain in patients. TARC (thymus and activation-regulated chemokine) *2 in blood is currently used as a diagnostic and severity marker of AD. In AD treatment, it is essential to properly assess the severity of the disease in order to provide appropriate treatment for the symptoms of each patient. The results of this study were presented at the International Societies for Investigative Dermatology: ISID 2023 Meeting (May 10–13, 2023, Tokyo) by Dr. This study was conducted in collaboration with Hidehisa Saeki, Graduate School Professor (Department of Cutaneous and Mucosal Pathophysiology, Graduate School of Medicine, Nippon Medical School), Takeshi Nakahara, Professor (Department of Clinical Medicine, Faculty of Medical Sciences, Kyushu University), Akio Tanaka, Professor (Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University), and Koji Masuda, Associate Professor (Department of Dermatology, Graduate School of Medicine, Kyoto Prefectural University of Medicine). This finding suggests the possibility of non-invasive and precise monitoring of a broader range of AD conditions, including severe cases, by analyzing SSL-RNA. analyzed sebum collected from adult patients with atopic dermatitis (AD) including severe cases and found that the skin surface lipids-RNA (SSL-RNA) *1 contains molecules that change depending on the severity of the disease. ![]() ![]() The research group at The Bioscience Laboratory of Kao Corporation and Maruho Co., Ltd.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |